Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Joseph A. Sparano, MD, of Montefiore Medical Center, discuss this study of high-risk premenopausal luminal A breast cancer patients receiving adjuvant chemotherapy (Abstract S1-08).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor-positive/HER2-negative disease. (Abstract S5-07)
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).
